Gastroesophageal Reflux Disease Market to Grow at a Substantial Growth Rate by 2032 - DelveInsight | Key Companies in the Market - Phathom Pharmaceuticals, Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca
December 12, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Gastroesophageal Reflux Disease Market to Grow at a Substantial Growth Rate by 2032 - DelveInsight | Key Companies in the Market - Phathom...
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
December 06, 2023 08:00 ET
|
Phathom Pharmaceuticals
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly...
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 28, 2023 08:00 ET
|
Phathom Pharmaceuticals
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available at major retail pharmacies and through BlinkRx.
Microbiome Therapeutics Market Size to Hit $813.38 Million, Globally, by 2030 - Exclusive Report by The Insight Partners
November 10, 2023 05:43 ET
|
The Insight Partners
Pune, India, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome's...
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 09, 2023 08:00 ET
|
Phathom Pharmaceuticals
VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
November 01, 2023 17:00 ET
|
Phathom Pharmaceuticals
FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 yearsVOQUEZNA® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3...
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 26, 2023 08:01 ET
|
Phathom Pharmaceuticals
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile...
4.9% CAGR for Gastrointestinal Drugs Market Size Worth $71.3Bn, Globally, by 2027 with Irritable Bowel Syndrome Segment Driving Growth During 2020-2027 | Report by The Insight Partners
July 11, 2023 10:55 ET
|
The Insight Partners
Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners latest study on "Gastrointestinal Drugs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug...
Global Pediatric Gastroenterology Market Size & Trends
June 23, 2023 10:59 ET
|
Global Market Estimates
Brooklyn, New York, June 23, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Pediatric Gastroenterology Market is projected to...
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
June 12, 2023 08:01 ET
|
Phathom Pharmaceuticals
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June...